Invivyd starts Phase 2 FLINTLOCK trial of VYD2311 antibody for Long COVID
What's happened? Invivyd and the SPEAR Study Group have started FLINTLOCK, a Phase 2 clinical trial of VYD2311, a high-dose monoclonal antibody candidate for Long COVID and Post-Vaccination Syndrome (also called COVID vaccine injury). The company announced recruitment on 14 October 2026.
The design: The randomised, double-blind, placebo-controlled proof-of-concept study will enrol adults aged 18-65. Patients receive an initial high-dose intravenous infusion of VYD2311 followed by monthly injections at days 30 and 60 — a total dose about 10 times the prophylactic dose, yet below levels already shown to have a positive initial safety profile in first-in-human testing. Outcomes are assessed over 90 days. VYD2311 has demonstrated antiviral activity in the lab against every SARS-CoV-2 variant tested, from the original Wuhan strain through contemporary Omicron variants.
Why it matters: Millions of people live with persistent, multi-system symptoms after COVID-19, and few treatment options exist. FLINTLOCK is part of Invivyd's broader REVOLUTION programme for VYD2311, which also includes the DECLARATION and LIBERTY studies.
Read more: BioSpace, 14 October 2026